Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- COEPW
- Price
- 0.01
- Stock movement up
- +0.00 (18.18%)
- Company name
- Coeptis Therapeutics Holdings Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- -
- Ent value
- -1.64M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -49.42%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
COEPW does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | -0.70 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | - |
| EPS (TTM) | -2.06 |
| FCF per share (TTM) | -1.76 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 2.36M |
| Gross profit (TTM) | -1.21M |
| Operating income (TTM) | -13.22M |
| Net income (TTM) | -9.76M |
| EPS (TTM) | -2.06 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -51.14% |
| Operating margin (TTM) | -559.11% |
| Profit margin (TTM) | -413.01% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 4.91M |
| Net receivables | 86.04K |
| Total current assets | 5.99M |
| Goodwill | 0.00 |
| Intangible assets | 1.21M |
| Property, plant and equipment | 268.79K |
| Total assets | 16.28M |
| Accounts payable | 783.10K |
| Short/Current long term debt | 279.87K |
| Total current liabilities | 2.71M |
| Total liabilities | 3.26M |
| Shareholder's equity | 13.02M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -8.35M |
| Capital expenditures (TTM) | 4.00 |
| Free cash flow (TTM) | -8.35M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -75.00% |
| Return on Assets | -59.96% |
| Return on Invested Capital | -73.43% |
| Cash Return on Invested Capital | -62.81% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.01 |
| Daily high | 0.01 |
| Daily low | 0.01 |
| Daily Volume | 16K |
| All-time high | 0.19 |
| 1y analyst estimate | - |
| Beta | -0.59 |
| EPS (TTM) | -2.06 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| COEPW | S&P500 | |
| Current price drop from All-time high | -93.33% | -0.89% |
| Highest price drop | -97.33% | -19.00% |
| Date of highest drop | 16 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -88.24% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 298 days | 89 days |
COMPANY DETAILS
Marketcap
-
Marketcap category
Small-cap
Description
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.
Employees
4
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner